NHAS
AVBP icon

Novo Holdings A/S’s ArriVent BioPharma AVBP Stock Holding History

Novo Holdings A/S’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.1M Sell
1,500,000
-442,142
-23% -$13M 3.03% 9
2026
Q1 		$44.8M Hold
1,942,142
– – 3.63% 11
2025
Q4 		$39.1M Hold
1,942,142
– – 3.03% 14
2025
Q3 		$35.8M Buy
1,942,142
+70,000
+4% +$1.38M 2.31% 14
2025
Q2 		$40.8M Hold
1,872,142
– – 2.88% 11
2025
Q1 		$34.6M Buy
1,872,142
+351,515
+23% +$8.6M 2.63% 12
2024
Q4 		$40.5M Buy
1,520,627
+15,312
+1% +$440K 2.45% 13
2024
Q3 		$35.4M Buy
1,505,315
+5,315
+0.4% +$121K 1.76% 15
2024
Q2 		$27.8M Buy
1,500,000
+422,860
+39% +$7.54M 1.5% 22
2024
Q1 		$19.2M Buy
+1,077,140
New +$21.7M 1.33% 25

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Novo Holdings A/S's AVBP Position: Q2 2026 in Review

Novo Holdings A/S reduced its ArriVent BioPharma (AVBP) stake by 23% in Q2 2026, selling an estimated $13M and leaving 1,500,000 shares worth $52.1M. The position accounts for 3.03% of the portfolio, ranked #9.

Novo Holdings A/S first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. 158 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Novo Holdings A/S held 1,500,000 shares of ArriVent BioPharma worth $52.1M as of Q2 2026.
  • Novo Holdings A/S sold 442,142 ArriVent BioPharma shares in Q2 2026, an estimated $13M.
  • ArriVent BioPharma made up 3.03% of Novo Holdings A/S's portfolio in Q2 2026, its #9 holding.
  • Novo Holdings A/S first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • 158 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Novo Holdings A/S's 13F filing for Q2 2026, filed 14 Aug 2026.